Tradestie Institutional Equity Comparison Engine · Market Close Oct 05, 2026

BLFS vs EKSO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BLFS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

BLFS Overall Winner 6-Pillar Tally: BLFS 6 – 0 EKSO Matrix Metrics: BLFS 9 – 1 EKSO

As of Oct 05, 2026, BioLife Solutions Inc. (BLFS) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLFS carries a Unified Composite Score of 46.0/100 (HOLD) at $38.61 (117.0x Forward P/E, 6.0% operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin).

  • Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. BLFS 46.0/100 HOLD), BLFS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (6.0% vs. -119.7% operating margin) and revenue trajectory (+21.5% vs. -38.3% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BLFS vs EKSO
BLFS NASDAQ Head-to-Head Winner
BioLife Solutions Inc.
Electromedical & Electrotherapeutic Apparatus
$38.61
+3.51% 1D
Market Cap $1.8B
TTM Revenue $107M
Forward P/E 117.0x
Beta / 30D Vol 1.05β · 31% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 27.0 Fund 46.0 Flow 59.0 Mom 56.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.2% over 20 days), RSI 61
RSI-14: 60.5 · SMA20: $37.08 · SMA50: $35.70
EKSO NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65

6-Pillar Scorecard Institutional Category Breakdown (BLFS 6 – 0 EKSO)

Columns: Metric · BLFS · EKSO
1. Valuation Multiples BLFS
Forward P/E 117.0x N/M
Trailing P/E 37.3x N/M
PEG Ratio N/M N/M
EV / Revenue 17.0x 3.3x
2. Growth & Scale BLFS
Revenue Growth (YoY) +21.5% -38.3%
Earnings Growth (YoY) -13.9% +0.0%
TTM Revenue (USD) $107M $13M
Market Cap $1.8B $42.0M
3. Profitability & Quality BLFS
Gross Margin 63.6% 53.5%
Operating Margin 6.0% -119.7%
Net Profit Margin 54.4% -91.4%
Return on Equity (ROE) 12.8% -107.6%
4. Balance Sheet & Cash Flow BLFS
Cash Generation (TTM) -$2.2M -$11M EBITDA
Cash Flow Margin -2.1% -86.0% EBITDA Mgn
Net Cash / Leverage $8.3M Net Cash $2.54 Book/Sh · -107.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BLFS
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 40.1% (6th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat BLFS
OpEx & R&D Intensity 57.6% of Rev ($61M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BLFS (9) vs EKSO (1)
Institutional Metric BLFS EKSO Criterion Row Edge
Market Capitalization
Scale
$1.8B $42.0M Larger Scale BLFS
Trailing P/E Ratio
Valuation
37.3x N/M Lower Multiple BLFS
Forward P/E Ratio
Valuation
117.0x N/M Lower Multiple BLFS
Revenue Growth (YoY)
Growth
+21.5% -38.3% Higher Growth BLFS
Operating Margin (TTM)
Profitability
6.0% -119.7% Higher Margin BLFS
Net Profit Margin
Profitability
54.4% -91.4% Higher Margin BLFS
Return on Equity (ROE)
Capital Efficiency
12.8% -107.6% Higher ROE BLFS
52-Week Range Position
Momentum
95% ($18–$40) 87% ($0–$14) Stronger Trend BLFS
Beta / 30D Volatility
Risk Regime
1.05β · 31% Vol 2.16β · 76% Vol Lower Realized Risk BLFS
Unified Institutional Score
Composite Signal
46.0 / 100 (HOLD) 58.1 / 100 (HOLD) Higher Composite EKSO
Trailing 12M Revenue (USD)
Operating Scale
$107M $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
63.6% 53.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 17.0x EV/Rev N/M PEG · 3.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.2M ($8.3M Net Cash) -$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EKSO +17.43 pp
BLFS: +8.1% · EKSO: +25.53%
3M Horizon EKSO +31.48 pp
BLFS: -5.55% · EKSO: +25.93%
6M Horizon EKSO +152.97 pp
BLFS: -21.6% · EKSO: +131.37%
1Y Horizon EKSO +140.4 pp
BLFS: -18.6% · EKSO: +121.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BLFS vs EKSO. Trailing 12-month operating profitability (BLFS 6.0% vs EKSO -119.7%) and valuation multiples (BLFS 117.0x vs EKSO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BLFS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$107M
Gross Margin63.6%
Op. Margin6.0%
ROE / Fwd P/E12.8% · 117.0x
EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BLFS BREAKOUT
38d in phase · OBV ACCUMULATION
Current IV 40.1%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact BLFS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BLFS Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $1.8B market capitalization and 6.0% operating margin.
OpEx & R&D Reinvestment 57.6% of Rev ($61M)
90D Engineering Disclosures 0 Published
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BLFS vs EKSO Key Questions & Quantitative Answers

As of Oct 05, 2026, BioLife Solutions Inc. (BLFS) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLFS carries a Unified Composite Score of 46.0/100 (HOLD) at $38.61 (117.0x Forward P/E, 6.0% operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin). Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. BLFS 46.0/100 HOLD), BLFS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (6.0% vs. -119.7% operating margin) and revenue trajectory (+21.5% vs. -38.3% YoY).

BLFS leads the Growth & Scale pillar: BLFS posts +21.5% YoY revenue growth and -13.9% YoY earnings growth on $107M TTM revenue (63.6% gross margin, 6.0% operating margin), compared with EKSO at -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin). On trailing 12-month operating scale, BLFS generates $107M in USD-normalized revenue versus $13M for EKSO. In operating R&D and SG&A reinvestment, BLFS deploys 57.6% of Rev ($61M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EKSO.

BLFS screens cheaper on headline valuation multiples. BLFS trades at 117.0x Forward P/E, 37.3x Trailing P/E, N/M PEG, and 17.0x EV/Revenue (-2.1% FCF margin), whereas EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BLFS (12.8% ROE) versus EKSO (-107.6% ROE) capital efficiency.

In options market volatility and institutional positioning, BLFS carries 40.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.05β · 31% Vol realized risk). By comparison, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Oct 05, 2026. For educational research only; not investment advice.